aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Delcath Systems, Inc., based in Queensbury, New York, is a specialty pharmaceutical and medical device company focused on developing percutaneous perfusion technologies for targeted high-dose chemotherapy. The company's core mission is to revolutionize the treatment of liver cancer through its innovative Percutaneous Hepatic Perfusion (PHP) system, which is currently in Phase II and Phase III clinical trials. Delcath holds an intellectual property portfolio of 28 patents worldwide, underscoring its commitment to advancing cancer treatment.
Delcath Systems has made significant strides in the medical field, particularly in the targeted administration of chemotherapeutic agents. The company's PHP system aims to improve outcomes for patients with liver cancer by delivering high-dose chemotherapy directly to the liver, minimizing systemic exposure and associated side effects. As a publicly traded company on NASDAQ under the ticker DCTH, Delcath continues to attract attention from investors and stakeholders dedicated to innovative cancer therapies.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Medical Devices, Chemotherapy
Technology
Biotech
Tags
Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Delcath Systems founded?
Delcath Systems was founded in 1987.
Where is Delcath Systems's headquarters located?
Delcath Systems's headquarters is located in Wilmington, DE, US.
When was Delcath Systems's last funding round?
Delcath Systems's most recent funding round was for $35M (USD) in September 2023.
How many employees does Delcath Systems have?
Delcath Systems has 58 employees as of Feb 6, 2024.
How much has Delcath Systems raised to-date?
As of July 05, 2023, Delcath Systems has raised a total of $269.6M (USD) since Sep 1, 2023.
Add Comparison
Total Raised to Date
$269.6M
USD
Last Update Sep 1, 2023
Last Deal Details
$35M
USD
Sep 1, 2023
Post Ipo Equity
Total Employees Over Time
58
As of Feb 2024
Delcath Systems Address
Wilmington,
Delaware
19801
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts